Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 4/20 | 0.42 |
| ▸ | ESRRB | O95718 | 3/20 | 0.42 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918047 | 0.86 | POLA1 (0.55) | POLA1AKR1B10AKR1B1SYKADORA2A | |
| Butane SCHEMBL5179499 | 0.80 | POLA1 (0.55) | POLA1AKR1B10AKR1B1SYKESRRG | |
| SCHEMBL6081018 | 0.79 | CA1 (0.54) | POLA1KDM4EALDH1A1CA12CA1 | |
| SCHEMBL1919137 | 0.79 | POLA1 (0.59) | POLA1AKR1B10AKR1B1SYKESRRG | |
| SCHEMBL5179500 | 0.79 | POLA1 (0.54) | POLA1AKR1B10AKR1B1SYKESRRG | |
| SCHEMBL1918021 | 0.76 | CA1 (0.57) | POLA1AKR1B10AKR1B1ALDH1A1CA12 | |
| SCHEMBL6413567 | 0.76 | NPC1 (0.51) | MAPTCA1CA2 | |
| SCHEMBL1918691 | 0.76 | GSK3B (0.55) | POLA1AKR1B10AKR1B1SYK | |
| SCHEMBL1918086 | 0.75 | POLA1 (0.55) | POLA1AKR1B10AKR1B1SYKKDM4E | |
| SCHEMBL27481085 | 0.75 | MAPT (0.67) | POLA1AKR1B10AKR1B1SYKADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | SCRAS | 2006-10-19 | — | — | US | claimed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | claimed |
| CN-1474689-A | CDC25 phosphatase inhibitors | ��ѧ�о���Ӧ����ѯ��˾ | 2004-02-11 | — | — | CN | claimed |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES | 2009-10-08 | — | — | US | disclosed |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-28 | — | — | US | disclosed |
| CN-100406449-C | CDC25 phosphatase inhibitors | SOD CONSEILS RECH APPLIC (FR) | 2008-07-30 | — | — | CN | disclosed |
| US-7196084-B2 | Cdc25 phosphatase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-12-14 | — | — | US | disclosed |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | SCRAS | 2006-10-19 | — | — | US | disclosed |
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | SCRAS | 2006-07-13 | — | — | US | disclosed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | disclosed |
| CN-1474689-A | CDC25 phosphatase inhibitors | ��ѧ�о���Ӧ����ѯ��˾ | 2004-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034103-A1 | Cdc25 photophatase inhibitors | CDC25C, CDC25A, CDC25B | POLA1 178/4885AKR1B10 2561/4885AKR1B1 1479/4885 |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | CDC25A, CDC25C, CDC25B | POLA1 473/4885AKR1B10 3074/4885AKR1B1 1833/4885 |
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | CDC25A, CDC25C, CDC25B | POLA1 1114/4885AKR1B10 4282/4885AKR1B1 3944/4885 |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | CDC25A, CDC25C, CDC25B | POLA1 406/4885AKR1B10 2621/4885AKR1B1 1307/4885 |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | CDC25A, CDC25C, CDC25B | POLA1 1114/4885AKR1B10 4282/4885AKR1B1 3944/4885 |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | CDC25A, CDC25C, CDC25B | POLA1 297/4885AKR1B10 3141/4885AKR1B1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.